Actively Recruiting
68Ga-JH04 PET/CT: Dosimetry and Biodistribution Studies
Led by First Affiliated Hospital of Fujian Medical University · Updated on 2024-11-14
5
Participants Needed
1
Research Sites
95 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
68Ga-JH04 is a novel radiotracer targeting fibroblast activation protein (FAP). In this study, we observed the safety, biodistribution, and radiation dosimetry of 68Ga-JH04 in patients with different types of cancer.
CONDITIONS
Official Title
68Ga-JH04 PET/CT: Dosimetry and Biodistribution Studies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of various solid tumors with available histopathological findings
- Signed informed consent
You will not qualify if you...
- Pregnant or breastfeeding women
- Severe liver or kidney insufficiency
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China, 350005
Actively Recruiting
Research Team
W
Weibing Miao, MD
CONTACT
G
Guochang Wang, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here